Skip to main content

Table 3 Cost-utility results (USD, 2020–2021 prices)

From: A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa

Strategy

Cost (USD)

QALYs

ICER (USD per QALY gained)

NPH once daily

32.27

0.8321

 

Detemir once daily

121.84

0.8343

Ext. dominated

Glargine U300

150.74

0.8351

40,104.91

Glargine U100

184.40

0.8344

Abs. dominated

Degludec

238.78

0.8365

64,831.20

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us